etoposide oral / Generic mfg. - LARVOL DELTA

Oral VP16 combined with ATRA and realgar-indigo naturalis formula as complete oral induction regimen is an fast,safe and effective regimen during induction to reduce mortality in high-risk acute promyelocytic leukemia (ASH 2025) - P4 | "Current international and Chinese guidelines recommend all-trans-retinoic acid (ATRA) plus arsenic tri-oxide, combined with either an anthracycline or cytarabine...To evaluate the efficacy and safety of oral etoposide combined with ATRA and RIF in high-risk APL, we have initiated a single-arm, prospective cohort study (ChiCTR2100053926). Once high-risk APL was suspected, ATRA 25mg/m 2 /day, hydroxyurea (Hu) and oral VP16 100-150 mg/day were given simultaneously...Nine (27.3%) pts used venetoclax to combinate with VP 16 with a median dose of 100 (50-300) mg... Compared with historical cases, oral VP16, instead of intravenous cytoreductive agent, in combination with ATRA and RIF as complete oral induction in high-risk APL, could control leukocytosis effectively and safely. Meanwhile high CR rate, RFS and OS could also achieve. In addition, this regimen is convenient for pts to receive fast and professional treatment as soon as possible without the limitation of space."

Acute Promyelocytic Leukemia • Cerebral Hemorrhage • Gastroenterology • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Novel Coronavirus Disease • CD34 • FLT3

Adult-onset non-langerhans histiocytosis with multisystem involvement and sustained remission on immunochemotherapy (ASH 2025) - "The patient was treated with oral etoposide 200 mg for 3 days every 21 days, in combination with oral prednisone, over the course of one year. Recognition of characteristic histopathologic and immunohistochemical profiles, in combination with imaging to exclude alternative diagnoses, is essential for accurate classification. Early recognition and initiation of immunochemotherapy can lead to durable remission, even in cases with multisystem involvement."

Clinical • CNS Disorders • Endometrial Cancer • Esophageal Cancer • General Anxiety Disorder • Hepatology • Hypertension • Langerhans Cell Histiocytosis • Mental Retardation • Mood Disorders • Rare Diseases • Respiratory Diseases • Solid Tumor • CD1a • CD68 • TNFRSF8

Oral etoposide vs intravenous daunorubicin plus ATRA-RIF as induction therapy for low-risk acute promyelocytic leukemia: A phase II randomized controlled Trial (ASH 2025) - P=N/A | "The data suggest a potential link between reduced cytoreductive dosingand increased relapse risk, while maintaining a manageable safety profile. Ongoing studies withextended follow-up will further define long-term outcomes."

Clinical • P2 data • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • CD34 • FLT3 • NCAM1 • PML

Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study (clinicaltrials.gov) - P2 | N=30 | Active, not recruiting | Sponsor: Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting ➔ Active, not recruiting | Trial completion date: May 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2025

Enrollment closed • Trial completion date • Trial primary completion date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

REAL-WORLD EXPERIENCE OF CABOZANTINIB MONOTHERAPY IN RELAPSED OR REFRACTORY OSTEOSARCOMA AND EWING SARCOMA: A SINGLE-CENTRE AUSTRALIAN STUDY (CTOS 2025) - "Following progression (n=9), one patient received oral etoposide, one received palliative radiation therapy, the remainder (n=7) did not receive further anti-cancer therapy... Our real-world data showed that CBZ monotherapy has clinically meaningful activity in osteosarcoma and ES, with acceptable toxicities. Validation in larger cohorts is warranted."

Clinical • Monotherapy • Real-world • Real-world evidence • Ewing Sarcoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

A Completely Oral Regimen Including Oral Etoposide As Cytoreductive Chemotherapy Combined with All Trans Retinoic Acid and Oral Arsenic for Induction Therapy in Patients with High-Risk APL:Comparable to Intravenous Cytoreductive Therapy (ASH 2023) - "A completely oral, efficient and safe induction regimen including oral VP16 as cytoreductive chemotherapy combined with ATRA and RIF is more convenient to administer for patients with high-risk APL."

Clinical • Acute Promyelocytic Leukemia • Cerebral Hemorrhage • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Novel Coronavirus Disease • Oncology • Respiratory Diseases

Cytoreductive Chemotherapy in Induction Therapy Plays a Key Role in the Prognosis of Patients with Low-Risk Acute Promyelocytic Leukemia (ASH 2023) - P=N/A | "Cytoreduction therapy, including hydroxycarbamide, anthracyclines and cytarabine during induction therapy was administrated based on the 2018 Chinese APL guidelines. In summary, the present study indicated that cytoreductive chemotherapy had a dual effect of both cytoreduction and prevention of relapse in low-risk APL. Oral etoposide as cytoreduction therapy combined with oral ATRA plus RIF is expected to be a regimen with low relapse, good tolerance and great convenience. A prospective, randomized, controlled, interventional study on oral etoposide versus intravenous daunorubicin for cytoreductive chemotherapy in induction therapy in patients with low-risk APL is now going on (NCT05832320)."

Clinical • Acute Promyelocytic Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Novel Coronavirus Disease • Oncology • PML • RARA

Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=10 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Oct 2025 ➔ Sep 2026 | Trial primary completion date: Oct 2025 ➔ Sep 2026

Trial completion date • Trial primary completion date • B Cell Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Gene Therapies • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD34

Maintenance Zanzalintinib With Etoposide After HDCT in GCT (clinicaltrials.gov) - P1/2 | N=38 | Recruiting | Sponsor: Indiana University | Not yet recruiting ➔ Recruiting | Trial completion date: Mar 2032 ➔ Sep 2031

Enrollment open • Trial completion date • Germ Cell Tumors

Adebrelimab combined with etoposide plus platinum followed by adebrelimab and etoposide soft capsules for maintenance treatment of extensive-stage small cell lung cancer: a single-arm phase II trial (ChiCTR) - P4 | N=40 | Recruiting | Sponsor: Jiangsu Cancer Hospital; Jiangsu Cancer Hospital

New P4 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

DEFYING THE ODDS: A LONG-TERM SURVIVAL WITH DIFFUSE MIDLINE GLIOMA H3K27M MUTATION. (SIOP 2025) - "To enhance the immune effect, a combination of bevacizumab and pembrolizumab was administered, leading to neurological improvement and tumor reduction. Maintenance therapy with irinotecan, bevacizumab, and temozolomide were also administered...She underwent reirradiation (25 Gy), along with oral etoposide and valproic acid until tumor progression in February 2020... The exceptional long-term survival of this child may reflect the benefits of multi-agent treatment, along with the integrative palliative care and family support provided in managing DIPG from the time of diagnosis."

IO biomarker • Brain Cancer • Diffuse Midline Glioma • Glioma • Palliative care • Pediatrics • Solid Tumor

HIGH-RISK MEDULLOBLASTOMA IN CHILDREN OLDER THAN FOUR YEARS OLD: A PROSPECTIVE ANALYSIS OF OUTCOME WITH CRANIOSPINAL RADIATION AND METRONOMIC THERAPY (SIOP 2025) - " Prospective study -Patients were treated with CSI 36Gy, concomitant carboplatin followed by maintenance CT cisplatin/cyclophosphamide-based and metronomic CT (oral etoposide, cyclophosphamide, fenofibrate and celecoxibe) for one year. We report the outcome of children with HR-MB treated in an upper middle-income country with CSI, maintenance and metronomic CT highlighting the potential role of metronomic CT in improving survival in this high-risk population."

Clinical • Brain Cancer • Medulloblastoma • Solid Tumor • MYC • MYCN

Real-world experience of cabozantinib monotherapy in relapsed or refractory osteosarcoma and Ewing Sarcoma: A single-centre Australian study (ESMO 2025) - "Following progression (n=8), one patient received oral etoposide, one received palliative radiation therapy, the remainder (n=6) did not receive further anti-cancer therapy...Validation in larger cohorts is warranted. Legal entity responsible for the study The authors."

Clinical • Monotherapy • Real-world • Real-world evidence • Ewing Sarcoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

FLUZOPARIB COMBINED WITH ORAL ETOPOSIDE IN ALTERNATING MAINTENANCE THERAPY FOR NEWLY DIAGNOSED ADVANCED OVARIAN CANCER (FARE TRIAL): A PROSPECTIVE, SINGLE-ARM, PHASE II STUDY (IGCS 2025) - "At interim analysis, a total of 14 participants received treatment, including 4 patients (28.6%) with BRCA1/2 mutations, 8 patients (57.1%) with wild-type BRCA1/2, and 2 patients (14.3%) with unknown BRCA1/2 status, 9 patients (64.3%) were homologous recombination deficiency (HRD) -positive, 2 (14.3%) were HRD-negative, and 3 (21.4%) had undetermined HRD status. Among them, 5 patients (35.7%) were diagnosed with FIGO IV Stage, and 9 patients (64.3%) with FIGO III Stage. Median follow-up duration was 26.5 months."

Clinical • Metastases • P2 data • Oncology • Ovarian Cancer • Solid Tumor • BRCA1 • BRCA2

Case report: Anlotinib plus oral etoposide: a potential salvage therapy based on insights from EGFR-TKI-resistant SCLC transformation PDX and clinical settings. (PubMed, Front Oncol) - "To our knowledge, this is the first report of anlotinib plus oral etoposide as a potential salvage therapy for patients with EGFR-TKI-induced SCLC transformation resistant to platinum-based chemotherapy. Both the PDX model and clinical cases support the efficacy of this regimen, providing a promising therapeutic option for patients with SCLC transformation after platinum-etoposide chemotherapy resistance."

Journal • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer (clinicaltrials.gov) - P2 | N=33 | Not yet recruiting | Sponsor: Fudan University

New P2 trial • Platinum resistant • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Solid Tumor

Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy (clinicaltrials.gov) - P2 | N=32 | Recruiting | Sponsor: Tang-Du Hospital

New P2 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Combination Therapy for Platinum-Resistant Ovarian Cancer: A Novel At-Home Regimen with Envafolimab, Lenvatinib, and Etoposide. (PubMed, Oncologist) - P2 | "Envafolimab combined with lenvatinib and etoposide showed promising efficacy and tolerable safety for patients with platinum-resistant recurrent ovarian cancer."

Journal • Platinum resistant • CNS Disorders • Depression • Hematological Disorders • Leukopenia • Mood Disorders • Oncology • Ovarian Cancer • Psychiatry • Solid Tumor • Thrombocytopenia

Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms (clinicaltrials.gov) - P2/3 | N=600 | Active, not recruiting | Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Trial completion date: Dec 2024 ➔ Dec 2026 | Trial primary completion date: Nov 2024 ➔ Nov 2026

Biomarker • Trial completion date • Trial primary completion date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Prognostic Value of Inflammatory Markers and Different Treatment Regimens in Neuroendocrine Cervical Carcinoma: A Retrospective Study (Frontiers) - "This single-center retrospective study included 25 NECC patients treated at our hospital between 2014 and 2024. Patients were divided into three groups based on treatment regimens: paclitaxel plus cisplatin combined with radiotherapy, etoposide plus cisplatin combined with radiotherapy, and radiotherapy alone....The median survival time was significantly longer in the etoposide plus cisplatin plus radiotherapy group (1,000 days) compared to the paclitaxel plus cisplatin plus radiotherapy group (776 days) and the radiotherapy-alone group (347 days, P = 0.037). The radiotherapy-alone group had significantly higher neutrophil counts (median = 5.46×10⁹/L, P = 0.006), platelet counts (median = 282.5×10⁹/L, P = 0.017), NLR (median = 4.68, P < 0.05), and PLR (median = 231.93, P < 0.05), while LMR (median = 1.89, P < 0.05) was lower."

Retrospective data • Cervical Cancer • Gynaecologic Neuroendocrine Carcinoma

Adjuvant Etoposide for Very High-Risk PFA Ependymoma: A Case Report. (PubMed, J Pediatr Hematol Oncol) - "This approach of using oral etoposide could be considered in ultra-high-risk 6q loss PF-A ependymoma to try and decrease the risk of relapse, awaiting further evaluation in a clinical trial."

Journal • Cardiovascular • CNS Disorders • Ependymoma • Hypertension • Oncology • Solid Tumor • Ventriculomegaly

Maintenance Zanzalintinib With Etoposide After HDCT in GCT (clinicaltrials.gov) - P1/2 | N=38 | Not yet recruiting | Sponsor: Indiana University | Initiation date: Apr 2025 ➔ Jul 2025

Trial initiation date • Germ Cell Tumors

A phase 2 study of sirolimus in combination with metronomic chemotherapy (CHOAnome) in children with recurrent and/or refractory solid and CNS tumors. (ASCO 2025) - P2 | "Treatment consisted of continuous sirolimus (2 mg/m2/dose PO daily), celecoxib (100 mg PO BID), and oral etoposide (50 mg/m2/day; max: 100 mg) alternating every 21 days with oral cyclophosphamide (2.5 mg/kg/day; max: 100 mg) in 42-day cycles. The combination of sirolimus with metronomic chemotherapy showed limited activity in patients with R/R solid tumors, although prolonged disease stabilization was seen across multiple histologies consistent with a metronomic approach."

Clinical • Combination therapy • P2 data • Brain Cancer • CNS Tumor • Ewing Sarcoma • Gastrointestinal Disorder • Nephrology • Neuroblastoma • Oncology • Osteosarcoma • Pediatrics • Rhabdomyosarcoma • Sarcoma • Soft Tissue Sarcoma • Wilms Tumor

Maintenance Zanzalintinib With Etoposide After HDCT in GCT (clinicaltrials.gov) - P1/2 | N=38 | Not yet recruiting | Sponsor: Indiana University

New P1/2 trial • Germ Cell Tumors

FUS Etoposide for DMG (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Columbia University | Suspended ➔ Recruiting

Enrollment open • Brain Cancer • CNS Tumor • Diffuse Intrinsic Pontine Glioma • Diffuse Midline Glioma • Glioma • Oncology • Solid Tumor